| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/07/2006 | US20060199842 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| 09/07/2006 | US20060199840 Chemical derivatives and their application as antitelomerase agent |
| 09/07/2006 | US20060199835 Neuroprotective and anti-proliferative compounds |
| 09/07/2006 | US20060199827 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 09/07/2006 | US20060199825 4-Aminating a 4-chloro-2-hydroxy-3-nitrodihydroquinoline with a N-(hetero)cyclylpiperazine, and alkylating the remaining amine group in the quinoline ring to produce a 4-(4-(hetero)cyclylpiperazinyl)-3-nitro-1-alkyldihydroquinolinone |
| 09/07/2006 | US20060199815 NK1 antagonists |
| 09/07/2006 | US20060199793 Sterol absorption inhibitor compounds |
| 09/07/2006 | US20060199791 Personal hygiene and hard surface cleaning agent; acne, skin complaints; effective against antibiotic resistant bacteria |
| 09/07/2006 | US20060199772 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 09/07/2006 | US20060199766 Pharmaceutical composition comprising a factor VIIa and a factor XIII |
| 09/07/2006 | US20060199759 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| 09/07/2006 | US20060199179 Method for diagnosis of colorectal tumors |
| 09/07/2006 | US20060198939 Porous ceramic composite bone grafts |
| 09/07/2006 | US20060198898 Orally administering edible oil homogenized with an edible wax at a concentration ranging from 0.5% to 50% by weight and a sterol compound at a concentration of at least 0.1% by weight for repairing and promoting regeneration of mucosa in the GI tract |
| 09/07/2006 | US20060198871 Methods for treating neovascularization and intravitreal implants |
| 09/07/2006 | US20060198846 Combinations for the treatment of diseases involving angiogenesis |
| 09/07/2006 | US20060198842 treating skeletal muscle atrophy with a corticotropin releasing factor 2 receptor (CRF2R) agonist such as Sauvagine, urocortin II or an antibody |
| 09/07/2006 | US20060198841 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 09/07/2006 | US20060198823 Compositions and methods for treating viral infections |
| 09/07/2006 | US20060196500 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage |
| 09/07/2006 | DE10038043B4 Phamakologisch wirksame Substanz zur Behandlung kardiovaskulärer Erkrankungen Of pharmacologically active substance for the treatment of cardiovascular diseases |
| 09/06/2006 | EP1698697A2 SSD-containing protein, process for producing the same and use thereof |
| 09/06/2006 | EP1698696A1 Target protein of antidiabetic agent and novel antidiabetic agent insuful corresponding thereto |
| 09/06/2006 | EP1698685A1 Fat composition |
| 09/06/2006 | EP1698627A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/06/2006 | EP1698348A1 Remedy/preventive for vascular disorders and hypertension and method of screening the same |
| 09/06/2006 | EP1698335A1 Preventive and/or therapeutic agent for disease in which mitochondrial benzodiazepine receptor participates |
| 09/06/2006 | EP1698330A1 Anti-inflammatory analgesic external preparation |
| 09/06/2006 | EP1697375A2 Heterocyclic protein kinase inhibitors and uses thereof |
| 09/06/2006 | EP1696959A2 Melatonin combination therapy for improving sleep quality |
| 09/06/2006 | EP1696958A1 Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| 09/06/2006 | EP1696939A2 Polymetaphosphate based formulations for therapy of microcrystalline arthropathies |
| 09/06/2006 | EP1696917A1 COMBINATION OF (a) N-{5- [4-(4-METHYL-PIPERAZINO-METHYL) -BENZOYLAMIDO] -2METHYLPHENYL]-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF |
| 09/06/2006 | EP1696909A1 Benzothiazole derivatives for the treatment of diabetes |
| 09/06/2006 | EP1696897A1 Compositions and methods for treating diabetes |
| 09/06/2006 | EP1696896A2 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
| 09/06/2006 | EP1696894A1 Treating infectious diseases using ice inhibitors |
| 09/06/2006 | EP1696893A1 Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass. |
| 09/06/2006 | EP1696874A1 Effervescent preparation of a basic medicinal substance |
| 09/06/2006 | EP1696859A2 Method for improving insulin sensitivity by administering an inhibitor of antitrypsin |
| 09/06/2006 | EP1696825A1 Use of alginate matrices to control cell growth |
| 09/06/2006 | EP1696737A1 Edible compositions which are adapted for use by a companion animal |
| 09/06/2006 | EP1551378A4 Epo d + 5-fu/gemcitabine |
| 09/06/2006 | EP1458673B1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) |
| 09/06/2006 | EP1453520B1 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances |
| 09/06/2006 | EP1406609B1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 09/06/2006 | EP1397145B1 Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders |
| 09/06/2006 | EP1385513B1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents |
| 09/06/2006 | EP1349553B1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain |
| 09/06/2006 | EP1345607B1 Therapeutic combination of amlodipine and benazepril / benazeprilat |
| 09/06/2006 | EP1326632B1 Proteasome inhibitors for the treatment of hepatitis virus infections |
| 09/06/2006 | EP1303308B1 Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |
| 09/06/2006 | EP1112075B1 Compositions for the treatment of male erectile dysfunction |
| 09/06/2006 | EP1071449B1 Use of an antagonist antibody to the inflammatory mediator oncostatin m (osm) |
| 09/06/2006 | EP0881912A4 Use of angiogenic lipids for vascularizing tissue |
| 09/06/2006 | EP0815204B1 Method for treating tumors by alloactivated human donor lymphocytes |
| 09/06/2006 | EP0789762B1 Methods for the diagnosis of glaucoma |
| 09/06/2006 | CN1829741A Treatment with anti-VEGF antibodies |
| 09/06/2006 | CN1829534A Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| 09/06/2006 | CN1829511A Use of angiotensin II receptor antagonists, especially telmisartan, in order to increase insulin sensitivity |
| 09/06/2006 | CN1829509A Combinations of drugs for the treatment of neoplasms |
| 09/06/2006 | CN1827646A Chemokine receptors 88-2b[ckr-3] and 88c and their antibodies |
| 09/06/2006 | CN1827170A Composition containing dihydropyridin type of calcium antagonists and fibrates medicine |
| 09/06/2006 | CN1827169A Composite preparation containing nitrate esters medicine and HMG-CoA reductase inhibitor |
| 09/06/2006 | CN1827168A Treatment of t cell mediated autoimmune disorders |
| 09/06/2006 | CN1273467C Beta-lactam compounds, process for producing the same and serum cholesterol-lowering agents containing the same |
| 09/06/2006 | CN1273195C Carbonized pollen and its application in preparation of cancer-treating medicine |
| 09/06/2006 | CN1273146C Composition for treating tumor |
| 09/06/2006 | CN1273141C Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate and preparation method thereof |
| 09/06/2006 | CN1273127C Perfume compositions |
| 09/06/2006 | CN1273112C Fibrate-statin combinations with food-reducing and -fasting function |
| 09/05/2006 | USRE39264 Pharmaceutical combination |
| 09/05/2006 | US7101995 Drug delivery to inhibit abnormal gene expression in mammalian cells; small interfering RNAs (siRNA) |
| 09/05/2006 | US7101977 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor |
| 09/05/2006 | US7101907 Topical administration of statins for treatment of bone disorders |
| 09/05/2006 | US7101893 Treating hyperproliferative disorders; N-(4-trifluoromethoxyphenyl) 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide |
| 09/05/2006 | US7101891 Compounds and pharmaceutical compositions for inhibiting MRP1 |
| 09/05/2006 | US7101889 Lipase inhibiting composition |
| 09/05/2006 | US7101876 Substituted benzoxazines as integrin antagonists |
| 09/05/2006 | US7101866 6,9-Difluoro-17 alpha -((2-furanylcarbonyl)oxy)-11 beta -hydroxy-16 alpha -methyl-3-oxo-androsta-1,4-diene-17 beta -carbothioic acid S-fluoromethyl ester; antiinflammatory agents for the treatment of allergic conditions |
| 09/05/2006 | US7101860 Composition and method for inhibiting platelet aggregation |
| 09/05/2006 | US7101853 Provided amylin agonist is not calcitonin; also amylin used in combination with an nonsteroidal antiinflammatory agent to relieve pain, thereby achieving a synergistic effect |
| 09/05/2006 | US7101850 WISP polypeptides and nucleic acids encoding same |
| 09/05/2006 | US7101846 Methods and compositions for optimization of oxygen transport by cell-free systems |
| 09/05/2006 | US7101842 Such as transferrin-doxorubicin conjugate linked by gluteraldehyde; inexpensive, effective |
| 09/05/2006 | US7101689 Interleukin-18 binding proteins, their preparation and use |
| 09/05/2006 | US7101576 Nanoparticles of megestrol, megestrol acetate, or a salt and a stabilizer is assocated with the surface of the nanoparticle |
| 09/05/2006 | US7101568 Biodegradation organophosphorus polymer; administering to tumor in situ |
| 09/05/2006 | US7101557 Promoting coagulation in prothrombotic blood vessels, treating a vascularized tumor with a coagulation-deficient tissue factor compound |
| 09/05/2006 | US7101553 Administering prebiotic such as fructo-oligosaccharide; measles prevention; vaccines; nutrients |
| 09/05/2006 | US7101550 Agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response |
| 09/05/2006 | US7101539 Increasing hematopoietic progenitor cells in a mammal by adminstering an interleukin-like polypeptide |
| 09/05/2006 | CA2393640C Pyrrolo[2,3-d]pyrimidine compounds |
| 08/31/2006 | WO2006091988A1 Composition for treating mental health disorders |
| 08/31/2006 | WO2006090932A1 Surrogate marker for sulfonamide compound |
| 08/31/2006 | WO2006090931A1 Novel concomitant use of sulfonamide compound with anti-cancer agent |
| 08/31/2006 | WO2006090930A1 Novel combinational use of sulfonamide compound |
| 08/31/2006 | WO2006090921A1 Inhibitory effect of sulfonamide compound on lymphocyte activation |
| 08/31/2006 | WO2006090910A1 Novel steroid glycoside, ngf-associated active substance, process for producing the same, method of screening thereof, and cerebral dysfunction preventive agent |
| 08/31/2006 | WO2006090900A1 Preventives/remedies for cancer |